Foam for enhanced topical delivery: An overview

Dermatologica Sinica

Volumn 25, Issue 1, 2007, Pages 10-15

  Tanojo, Hanafi ^a   Huang, Xinfan ^a   Maibach, Howard I ^b  

^a Genepharm Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aerosol; Drug delivery; Foam; Topical dosage form

Indexed keywords

BETAMETHASONE VALERATE; CLINDAMYCIN PHOSPHATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; EMOLLIENT AGENT; FELBINAC; HEXACHLOROPHENE; HYDROCORTISONE; KETOCONAZOLE; PERMETHRIN; PHENOTHRIN; PIMECROLIMUS; POVIDONE IODINE; PRAMOCAINE; PYRITHIONE ZINC; TACROLIMUS;

DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; FOAM; HEAT SENSITIVITY; HUMAN; HYDRATION; IN VITRO STUDY; PATIENT COMPLIANCE; PSORIASIS; REVIEW; SKIN PENETRATION; STRATUM CORNEUM;

EID: 33947252241     PISSN: 10278117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Hess H. Pharmaceutical Dosage Forms and Their Use. Basle: Ciba-Geigy, 1985.
2. Wester RC, Maibach HI: Cutaneous Pharmacokinetics: 10 Steps to Percutaneous Absorption. Drug Metab Rev 14: 169-205. 1983.
3. George YA, Ravis SM, Gottlieb J, et al.: Betamethasone valerate 0.12% in foam vehicle for scalp seborrheic dermatitis in African Americans. Cosmet Dermatol 15: 23-27. 2002.
4. Wasan DT: Foam and emulsion stability: Interfacial rheology and thin liquid film phenomena. In: Emulsions, Foams and Thin Films (Mittal KL, Kumar P, eds). New York: Marcel Dekker: 1-30. 2000.
5. Woodford R, Barry BW: Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam. J Pharm Sci 66: 99-103, 1977.
6. Huang X, Tanojo H, Lenn J et al.: A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 53: S26-S38, 2005.
7. Tamarkin D, Friedman D, Shemer A: Emollient foam in topical drug delivery. Expert Opin Drug Deliv 3: 799-807, 2006.
8. Tanojo H, Lenn J, Huang X: Skin permeation profile of clindamycin in foam and gel formulations. In: American Academy of Dermatology Annual Meeting. Washington, D.C.: P668. 2004.
9. Huang X, Tanojo H, Lenn J, et al.: Impact of vehicle on clobetasol propionate skin permeation and drug distribution in vitro. In: American Academy of Dermatology Annual Meeting. Washington, D.C.: P695. 2004.
10. Lenn J, Tanojo H, Huang X: Anatomical region variations on the in vitro skin permeation of clobetasol propionate formulations. In: American Academy of Dermatology Annual Meeting. Washington, D.C.: P678. 2004.
11. Tanojo H, Lenn J, Sykes J, et al.: Effects of co-application of betamethasone 17-valerate and tacrolimus on skin penetration and distribution of each drug in vitro. In: American Academy of Dermatology Annual Meeting. San Francisco: P342. 2003.
12. Deng H, Tanojo H, Lenn J, et al.: In vitro human skin study of combined application of pimecrolimus cream and betamethasone 17-valerate. In: American Academy of Dermatology Annual Meeting. Washington, D.C.: P694. 2004.
13. Franz TJ, Parsell DA, Halualani RM, et al.: Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 38: 628-632, 1999.
14. Franz TJ, Parsell DA, Myers JA, et al.: Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 39: 535-538, 2000.
15. Andreassi L, Giannetti A, Milani M: Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 148: 134-138, 2003.
16. Bates B: Not just for the scalp anymore betamethasone valerate foam battles body psoriasis. Skin & Allergy News 31. 2000.
17. Rekacewicz I, Guillaume JC, Benkhraba F, et al.: [A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor]. Ann Dermatol Venereol 117: 709-711, 1990.
18. Huang X, Tanojo H, Lenn J, et al.: Impact of formulation on ketoconazole skin penetration and drug distribution in vitro. In: American Academy of Dermatology Annual Meeting. San Francisco: P316. 2003.
19. Purdon CH, Haigh JM, Surber C, et al.: Foam drug delivery in dermatology: Beyond the scalp. Am J Drug Deliv 1: 71-75, 2003.
20. Housman TS, Mellen BG, Rapp SR, et al.: Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 70: 327-332, 2002.
21. Gottlieb AB, Ford RO, Spellman MC: The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7: 185-192, 2003.